Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RNXT
RNXT logo

RNXT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy RenovoRx Inc (RNXT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.910
1 Day change
52 Week Range
1.450
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

RenovoRx Inc (RNXT) is not a strong buy at this time for a beginner investor with a long-term strategy. The technical indicators show mixed signals with a bearish moving average trend, and there are no significant positive catalysts or trading signals to support immediate action. Additionally, the lack of financial data, news, and valuation metrics makes it difficult to assess the company's long-term growth potential. Holding off on this investment for now is the most prudent course of action.

Technical Analysis

The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 63.092, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 0.959), which could limit further upward movement in the short term. Overall, the technical analysis suggests a mixed outlook.

Positive Catalysts

  • NULL identified. There is no recent news, no significant insider or hedge fund activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The stock has a high probability of declining in the short term based on candlestick pattern analysis (-1.11% in the next day, -2.01% in the next week). Additionally, the bearish moving averages and lack of positive trading trends suggest limited upward momentum.

Financial Performance

No financial data available for analysis due to an error in the provided data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes were provided for this stock.

Wall Street analysts forecast RNXT stock price to rise
4 Analyst Rating
Wall Street analysts forecast RNXT stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.910
sliders
Low
3
Averages
5.63
High
12.5
Current: 0.910
sliders
Low
3
Averages
5.63
High
12.5
JonesResearch
Justin Walsh
initiated
$8
AI Analysis
2026-01-29
Reason
JonesResearch
Justin Walsh
Price Target
$8
AI Analysis
2026-01-29
initiated
Reason
JonesResearch analyst Justin Walsh initiated coverage of RenovoRx with a Buy rating and $8 price target. RenovoRx is a commercial stage medical technology company with an FDA-cleared dual-balloon catheter, RenovoCath, designed to improve delivery of anti-cancer drugs to tumors with poor blood supply, the analyst tells investors in a research note. The firm sees the device being "particularly useful" for treating pancreatic cancer.
Alliance Global
Buy
maintain
$3
2025-11-14
Reason
Alliance Global
Price Target
$3
2025-11-14
maintain
Buy
Reason
Alliance Global lowered the firm's price target on RenovoRx to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q3 earnings that were within expectations. The firm cites lower forecasts and modestly higher expected dilution for its reduced target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for RNXT
Unlock Now

People Also Watch